Document is current
Any future updates will be listed below
-
Authors
Prochaska, Jürgen H.
Jünger, Claus
Schulz, Andreas
Arnold, Natalie
Müller, Felix
Heidorn, Marc William
Baumkötter, Rieke
Zahn, Daniela
Koeck, Thomas
Tröbs, Sven-Oliver
Lackner, Karl J.
Daiber, Andreas
Binder, Harald
Shah, Sanjiv J.
Gori, Tommaso
Münzel, Thomas
Wild, Philipp S. https://orcid.org/0000-0003-4413-9752
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02932436 at ClinicalTrials.govDocuments that mention this clinical trial
156 Effects of a low-energy meal replacement programme on reverse cardiac remodelling in asymptomatic people with type 2 diabetes: a comparison between south asians and white europeans
https://doi.org/10.1136/heartjnl-2022-bcs.156
Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial
https://doi.org/10.1186/s12933-025-02916-0
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial
https://doi.org/10.1007/s00392-023-02164-w
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
Bundesministerium für Bildung und Forschung (BMBF 01EO1503, BMBF 161L0217A)
Deutsches Zentrum für Herz-Kreislaufforschung
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 28 June 2022
Accepted: 12 December 2022
First Online: 10 February 2023
Declarations
:
: Dr. Prochaska has received honoraria for lectures from Boehringer Ingelheim and Bayer AG outside the topic of the present study. Dr. Wild has received research funding outside the topic of the present study from Boehringer Ingelheim, Sanofi-Aventis, Bayer Healthcare, Daiichi Sankyo Europe, and Novartis, and received outside the topic of the present study honoraria for lectures or consulting from Boehringer Ingelheim, Bayer HealthCare, Evonik, AstraZeneca and Sanofi-Aventis. Dr. Tröbs has received lecture fees for Philips AG outside the submitted work. Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapies, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards, Eidos, Eisai, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Sanofi, Shifamed, Tenax, and United Therapeutics.
: Dr. Jürgen H. Prochaska, Dr. Andreas Schulz, Dr. Natalie Arnold, Dr. Felix Müller, Dr. Marc William Heidorn, Rieke Baumkötter, Dr. Daniela Zahn, Dr. Thomas Koeck, Dr. Sven-Oliver Tröbs, Dr. Karl J. Lackner, Dr. Andreas Daiber, Dr. Harald Binder, Dr. Sanjiv J. Shah, Dr. Tommaso Gori, Dr. Thomas Münzel, Dr. Philipp S. Wild, Dr. Steffen Rapp; Interdisciplinary Center for Clinical Trials (IZKS) Mainz (i.e., Dr. Silke Warnke, Dr. Kai Kronfeld, Dr. Christian Ruckes, Christoph Medler).
